US 11,684,614 B2
Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
Rebecca J. Abergel, Kensington, CA (US); Taylor A. Choi, South San Francisco, CA (US); Kenneth N. Raymond, Berkeley, CA (US); and David K. Shuh, Oakland, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Appl. No. 16/330,601
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
PCT Filed Sep. 5, 2017, PCT No. PCT/US2017/050121
§ 371(c)(1), (2) Date Mar. 5, 2019,
PCT Pub. No. WO2018/048812, PCT Pub. Date Mar. 15, 2018.
Prior Publication US 2021/0283115 A1, Sep. 16, 2021
Int. Cl. A61K 31/444 (2006.01); A61P 39/04 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01)
CPC A61K 31/444 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0056 (2013.01); A61K 9/0095 (2013.01); A61K 9/1611 (2013.01); A61K 9/1623 (2013.01); A61K 9/1652 (2013.01); A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61P 39/04 (2018.01)] 18 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising:
a 1,2-HOPO chelating agent in an amount from about 100 to about 1500 mg; and
sodium oleate,
wherein the 1,2-HOPO chelating agent is 3,4,3-L1-1,2-HOPO.